Compare Amylx Pharmaceuticals Inc (AMLX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Verisign, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $23.59 (market cap $2.64B), while Verisign, Inc. trades at $284.09 (market cap $26.00B). The key difference: Verisign, Inc. is far larger — about 9.8× Amylx Pharmaceuticals Inc's market cap, and Verisign, Inc. pays a 1.13% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | VRSN | |
|---|---|---|
Market Cap | $2.64B | $26.00B |
Sector | Health | Technology |
52-Week High | $24.19 | $310.00 |
52-Week Low | $7.82 | $211.49 |
Enterprise Value | $2.39B | $27.31B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
VeriSign (VRSN) trades at $283.56, down 3.33% today, amid mixed quarterly earnings but maintains a bullish technical trend with strong moving averages. The company reported Q2 2026 revenue of $435 million, up 6% year-over-year, with EPS of $2.38 beating estimates. Recent delegation of the .web domain and AI-driven registration growth support a positive outlook, though valuation ratios like P/E of 31.23 suggest a premium.
The stock offers upside to the consensus price target of $320, driven by domain growth and pricing power, but risks include high debt levels and reliance on .com/.net contracts. Analyst sentiment is bullish with 60% buy ratings, yet investors should monitor execution on guidance and contract renewals for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
